Our top pick for
Translate Bio, Inc is a biotechnology business based in the US. Translate Bio shares (TBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Translate Bio employs 93 staff and has a trailing 12-month revenue of around USD$91.3 million.
Since the stock market crash in March caused by coronavirus, Translate Bio's share price has had significant positive movement.
Its last market close was USD$16.6, which is 52.47% up on its pre-crash value of USD$7.89 and 144.12% up on the lowest point reached during the March crash when the shares fell as low as USD$6.8.
If you had bought USD$1,000 worth of Translate Bio shares at the start of February 2020, those shares would have been worth USD$1,467.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,367.99.
|Latest market close||USD$16.6|
|52-week range||USD$6.8 - USD$26.32|
|50-day moving average||USD$15.0508|
|200-day moving average||USD$15.9114|
|Wall St. target price||USD$30.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.395|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||N/A|
|1 month (2020-10-30)||29.38%|
|3 months (2020-08-26)||N/A|
|6 months (2020-05-26)||N/A|
|1 year (2019-11-26)||N/A|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$91.3 million|
|Gross profit TTM||USD$-38,880,000|
|Return on assets TTM||-4.28%|
|Return on equity TTM||-23.49%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 10.8 million Translate Bio shares held short by investors – that's known as Translate Bio's "short interest". This figure is 0.3% up from 10.8 million last month.
There are a few different ways that this level of interest in shorting Translate Bio shares can be evaluated.
Translate Bio's "short interest ratio" (SIR) is the quantity of Translate Bio shares currently shorted divided by the average quantity of Translate Bio shares traded daily (recently around 897016.98425849). Translate Bio's SIR currently stands at 12.07. In other words for every 100,000 Translate Bio shares traded daily on the market, roughly 12070 shares are currently held short.
However Translate Bio's short interest can also be evaluated against the total number of Translate Bio shares, or, against the total number of tradable Translate Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Translate Bio's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Translate Bio shares in existence, roughly 150 shares are currently held short) or 0.3072% of the tradable shares (for every 100,000 tradable Translate Bio shares, roughly 307 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Translate Bio.
Find out more about how you can short Translate Bio stock.
We're not expecting Translate Bio to pay a dividend over the next 12 months.
Over the last 12 months, Translate Bio's shares have ranged in value from as little as $6.8 up to $26.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Translate Bio's is 0.3289. This would suggest that Translate Bio's shares are less volatile than average (for this exchange).
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.